These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22951844)

  • 41. [Therapeutic strategies. Evolution and current status of the European Guidelines on Cardiovascular disease prevention].
    Guijarro C; García-Díaz Jde D
    Clin Investig Arterioscler; 2013; 25(2):92-7. PubMed ID: 23769961
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Recommendations for management of dyslipidemia in 2014].
    Moser M; Gencer B; Rodondi N
    Rev Med Suisse; 2014 Mar; 10(420):518, 520-4. PubMed ID: 24701669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Dyslipidemias: is it necessary to treat or not treat? An approach based on scientific evidence in 2011].
    Rodondi N
    Rev Med Suisse; 2011 May; 7(294):1037-8. PubMed ID: 21692326
    [No Abstract]   [Full Text] [Related]  

  • 44. [Lipid management--treatment goal and strategy].
    Koshiyama H
    Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [European Guidelines on Cardiovascular Disease Prevention in the Clinical Practice. Third work group of the european societies and other societies on cardiovascular disease prevention in the clinical practice].
    de Backer G; Ambrosioni E; Borch-Johnsen K; Brotons C; Cifkova R; Dallongeville J; Ebrahim S; Faergeman O; Graham I; Mancia G; Manger Cats V; Orth-Gomer K; Perk J; Pyorala K; Rodicio JL; Sans S; Sansoy V; Sechtem U; Silber S; Thomsen T; Wood D
    Neurologia; 2004 Oct; 19(8):440-50. PubMed ID: 15470585
    [No Abstract]   [Full Text] [Related]  

  • 46. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.
    Bongard V; Dallongeville J; Arveiler D; Ruidavets JB; Amouyel P; Wagner A; Ferrières J
    Arch Cardiovasc Dis; 2013 Feb; 106(2):93-102. PubMed ID: 23527913
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipid-lowering pharmacotherapy in Central and Eastern European countries in cardiovascular prevention: self-reported prescription patterns of primary care physicians.
    Tomasik T; Windak A; Seifert B; Kersnik J; Kijowska V; Dubas K
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):234-42. PubMed ID: 23277158
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of dyslipidaemia in childhood.
    Kusters DM; Vissers MN; Wiegman A; Kastelein JJ; Hutten BA
    Expert Opin Pharmacother; 2010 Apr; 11(5):739-53. PubMed ID: 20210683
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Cardiology update in 2016].
    Gabus V; Tran VN; Regamey J; Pascale P; Monney P; Hullin R; Vogt P
    Rev Med Suisse; 2017 Jan; 13(544-545):27-32. PubMed ID: 28703531
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A simple multiplier to calculate the impact of HDL cholesterol on cardiovascular risk estimation using SCORE.
    Descamps OS; Cooney MT; De Backer G; Graham I
    Atherosclerosis; 2012 Jun; 222(2):564-6. PubMed ID: 22560327
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Novel algorithms in treatment of dyslipidemia: comparative analysis of new American and European recommendations].
    Mamedov MN; Kovrigina MN; Toguzova ZA
    Kardiologiia; 2015; 55(1):77-81. PubMed ID: 26050497
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Therapeutic Strategies. Cardiovascular risk and dyslipidemia in elderly and women].
    Morales C; Royuela M
    Clin Investig Arterioscler; 2013; 25(3):146-50. PubMed ID: 23786854
    [TBL] [Abstract][Full Text] [Related]  

  • 53. News from the literature: focus on joint ESC/EAS dyslipidemia guidelines.
    Stock J
    Atherosclerosis; 2012 Jan; 220(1):42-4. PubMed ID: 22093725
    [No Abstract]   [Full Text] [Related]  

  • 54. Primary prevention of cardiovascular diseases by lipid-lowering treatment in German general practice: results from GPs ignoring guidelines and risk calculators.
    Oriol-Zerbe C; Abholz HH
    Eur J Gen Pract; 2007; 13(1):27-34. PubMed ID: 17366291
    [TBL] [Abstract][Full Text] [Related]  

  • 55. European guidelines on cardiovascular disease prevention in clinical practice: past, present, and future: a need for joint forces.
    Cífková R; Mancia G; Kjeldsen SE; Laurent S
    J Hypertens; 2008 Feb; 26(2):157-60. PubMed ID: 18192823
    [No Abstract]   [Full Text] [Related]  

  • 56. European guidelines on cardiovascular disease prevention.
    Boysen G
    Int J Stroke; 2009 Apr; 4(2):71. PubMed ID: 19383045
    [No Abstract]   [Full Text] [Related]  

  • 57. Comments on the European guidelines on cardiovascular disease prevention.
    Aessopos A; Farmakis D
    Eur Heart J; 2004 Apr; 25(7):619; author reply 620. PubMed ID: 15120062
    [No Abstract]   [Full Text] [Related]  

  • 58. [LDL apheresis: an update and overview. LDL apheresis in Sardinia, Italy (SMILDLa)].
    Stefanutti C; Di Giacomo S; Morozzi C
    G Ital Nefrol; 2012; 29 Suppl 54():S14-8. PubMed ID: 22388823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Benchmarking progress in the implementation of the Fourth Joint Societies' Task Force Guidelines on the Prevention of Cardiovascular Disease in Clinical Practice.
    Morgan K; Burke H; McGee H
    Eur J Prev Cardiol; 2013 Feb; 20(1):54-60. PubMed ID: 22345672
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pediatric lipid management: an earlier approach.
    Zachariah JP; Johnson PK
    Endocrinol Metab Clin North Am; 2014 Dec; 43(4):981-92. PubMed ID: 25432392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.